OncoBEAM™ Blood Test – Detection of Tumor DNA in blood

Based on the data from the sequencing of your tumor DNA and using blood plasma samples, IndivuTest can perform blood tests in cooperation with the partner company Sysmex Inostics GmbH, making it possible to monitor the success of therapy, detect recurrence of the cancer early on, and identify changes in the tumor DNA during drug therapy. This enables therapeutic measures to be initiated or a medication switch to be made as early as possible. Moreover, the technology can also be used to identify treatment-relevant mutations in cancer cells if tumor tissue is not available or cannot be harvested for testing.

The method is based on technology developed at the Johns Hopkins University in the USA and offered by Sysmex Inostics GmbH (formerly a subsidiary of the Indivumed group). In this process, the methodology uses the characteristic of tumors to release very small amounts of DNA from the cancer tissue into the bloodstream, and it allows even individual DNA molecules to be reliably found in the blood and analyzed.

As part of the overall diagnostic testing, IndivuTest offers you the option of arranging for the blood test in cooperation with Sysmex Inostics.

To set this up, please speak to your oncologist who will then contact us.

Details about Sysmex Inostics GmbH are available on the website.